Medical Use
Cablivi is a vWF-directed antibody fragment used to treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with immunosuppressive therapy and plasma exchange.
Recommended Dosage:
- Initiation of Therapy: Start Cablivi injection at the beginning of plasma exchange therapy.
- -First Day: Administer 11 mg of Cablivi via bolus IV injection at least 15 minutes before plasma exchange, followed by 11 mg via subcutaneous (SC) injection after the plasma exchange.
- -Subsequent Days: Administer 11 mg of Cablivi via SC injection once daily after each plasma exchange.
- -Post-Plasma Exchange Period: Continue administering 11 mg of Cablivi via SC injection once daily for one month after the final plasma exchange. If signs of persistent underlying disease are present, therapy may be extended for at least 28 days.
Discontinuation: Stop Cablivi treatment if the patient experiences more than two recurrences of aTTP while on therapy.
Warning & Precautions
Severe Bleeding Risk: Severe bleeding may occur, especially in patients with underlying coagulopathies. If clinically significant bleeding happens, stop Cablivi 11 mg injection treatment. Discontinue treatment 7 days before any elective surgery, dental procedures, or other invasive interventions.
Hypersensitivity Reactions: Do not use Cablivi in patients with known severe hypersensitivity to this medication or any of its excipients. Hypersensitivity reactions, including urticaria, have been reported.
Pregnancy: Follow your healthcare provider’s instructions when using Caplacizumab-yhdp during pregnancy. This medication may increase the risk of bleeding in both the mother and the baby.
Documentation Availability
Documents required to import CABLIVI to India?
CABLIVI (caplacizumab-yhdp) injections can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing CABLIVI (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for Cablivi®?
The generic name for Cablivi® is Caplacizumab-yhdp.
Who Manufactures Cablivi®?
Cablivi® is manufactured by Ablynx.
Is Cablivi® FDA Approved?
Yes, Cablivi® was approved by the FDA on February 6, 2019.
What is the Dosage and Form of Cablivi®?
Cablivi® is available as an injection: 11 mg of lyophilized powder in a single-dose vial for intravenous administration.
What are the Common Side Effects of Cablivi®?
Common side effects include headache, nosebleed, and bleeding gums.
How Much Does Cablivi® Cost in India? Cablivi®?
The cost of Cablivi® in India varies. To procure this medication for aTTP legally, you can reach out to Rx4u team.
How Should Cablivi® be Stored?
Store Cablivi® refrigerated at 2-8°C (36-46°F) in the original carton to protect from light. Avoid freezing. Unopened vials can be stored at room temperature up to 30°C (86°F) for a single period of up to two months.
Is it safe to buy Cablivi® online in India?
Yes, you can safely purchase Cablivi® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
